Skip to main content
Premium Trial:

Request an Annual Quote

ProMetic to Raise $9.8M in Private Placement

NEW YORK, June 5 (GenomeWeb News) - ProMetic Life Sciences will raise C$10.8 million, or $9.8 million, through a private placement of 29.6 million subordinate voting shares, the company said on Friday.


The private placement will be with JPMorgan and Third Point.


ProMetic will use the funds raised for general corporate purposes, including accelerating the development of PBI-1402, ProMetic's lead therapeutic, an orally active drug for the treatment of anemia in cancer patients undergoing chemotherapy.


The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.